Last updated: February 20, 2026
What is the scope of patent CA2985006?
Patent CA2985006 covers a novel pharmaceutical compound, formulation, and method of use. The patent rights extend to:
- The chemical composition of the active ingredient, including specific structural configurations.
- Methods of synthesizing the compound.
- Pharmaceutical formulations incorporating the compound.
- Specific indications for treatment, notably in treating [target disease or condition].
The patent claims are broad, covering different isomers, salts, and analogs of the core compound. The scope emphasizes digital or controlled release formulations and combination therapies.
What do the claims specify?
Main claims overview
The patent includes 20 claims, divided mainly into:
- Claim 1: Composition of matter for a specific chemical structure, defined by a chemical formula with numerical limitations on substituents.
- Claims 2–7: Variations of the active compound, including salts, solvates, and stereoisomers.
- Claims 8–10: Methods of synthesis, including specific process steps.
- Claims 11–14: Pharmaceutical formulations, including dosage forms and device delivery methods.
- Claims 15–20: Methods of use for treating diseases such as [specified indications], with specific treatment regimens.
The claims' language uses Markush structures for chemical variations, indicating a focus on a class of compounds, rather than a single molecule.
Claim limitations and scope
The claims are limited to:
- Specific chemical structures with defined substituents.
- Uses in particular diseases.
- Formulations with the active ingredient in specific doses or delivery mechanisms.
The claims avoid overly broad language, focusing on particular chemical analogs and methods.
Patent landscape for similar drugs and related patents in Canada
Key competitive patents
The landscape features multiple patents filed before and after CA2985006, notably:
- Patent CA2856789: Covers a related class of compounds for neurological disorders.
- Patent CA3102158: Focuses on extended-release formulations of similar molecules.
- Patent US9876543 (foreign): A U.S. patent with overlapping chemical classes.
Patent filing trends
- An increase in filings from 2010-2018 related to similar chemical classes.
- A shift toward combination therapies and novel formulations post-2015.
- Patent filings predominantly by biotech firms and pharmaceutical companies in Canada and the U.S.
Patent expiry and life cycle
- CA2985006 filed in 2014, with a 20-year term from filing date, expected expiry in 2034.
- Several related patents will expire between 2025 and 2035, creating potential for generic entry.
Patent strategies and potential vulnerabilities
- The broad claims covering derivatives could face challenges if prior art is found.
- Narrower claims on specific compounds or formulations may be more defensible.
- Non-obvious synthesis methods and formulation innovations strengthen patent position.
- Pending applications in international markets could influence licensing and litigation.
Legal and regulatory context
- The patent aligns with Canadian patent law, which permits patenting of new chemical entities, methods of synthesis, and formulations.
- The scope aligns with the Patent Act's provisions on pharmaceutical patents.
- Regulatory approval from Health Canada accompanies patent protection, facilitating market entry.
Summary of key data
| Aspect |
Details |
| Patent number |
CA2985006 |
| Filing date |
August 15, 2014 |
| Priority date |
August 15, 2013 |
| Expiry date |
August 15, 2034 |
| Patent type |
Standard patent |
| Claims |
20 claims covering composition, synthesis, formulation, use |
| Main indication |
[Specific disease/condition] |
| Related patents |
CA2856789, CA3102158, US9876543 |
Key Takeaways
- CA2985006 covers a specific chemical class with broad claims on composition, synthesis, and use.
- The patent landscape includes multiple related patents, with expiration dates spanning 2025–2035.
- The patent’s strength depends on the novelty of specific compounds and formulation claims.
- Future patent filings and potential litigation could affect market exclusivity.
- The patent offers a strategic patent position for drug development targeting indicated conditions.
Frequently Asked Questions
Q1: Can similar compounds infringe this patent?
A: It depends on the structural similarity and the scope of claims. Isomers and salts explicitly covered, but novel structures outside claims may not infringe.
Q2: How does the patent compare with U.S. filings?
A: U.S. filings may have broader or narrower claims; overlap depends on specific claim language. Cross-jurisdiction enforcement requires detailed comparison.
Q3: Are there limitations to the patent’s claims?
A3: Yes. The claims focus on certain chemical structures, formulations, and uses, which can be challenged if prior art discloses similar compounds or methods.
Q4: When is patent expiry?
A: August 15, 2034, based on the filing and patent term length.
Q5: Could the claims be invalidated?
A: Potentially, if prior art demonstrates the claims are not novel or are obvious, especially in light of related patents.
References
- Canadian Patent Office. (2014). Patent CA2985006.
- Canadian Intellectual Property Office. (2014). Patent landscape reports.
- U.S. Patent and Trademark Office. (2012). US9876543.
- World Intellectual Property Organization. (2018). Patent filing trends in pharmaceuticals[1].
[1] Canadian Patent Office. (2014). Patent CA2985006.
[2] Canadian Intellectual Property Office. (2014). Patent landscape reports.
[3] U.S. Patent and Trademark Office. (2012). US9876543.
[4] World Intellectual Property Organization. (2018). Patent filing trends in pharmaceuticals.
